

PET [89Zr]DFO-starPEG in Solid Tumors

NCT06894745

| | |
|------------|-------------------------|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Robert Flavell, MD, PhD |
| Enrollment | 13 participants |

Key Eligibility Criteria

Inclusion (13)

- Histological or cytological confirmation of solid tumor malignancy.
- Any solid tumor malignancy, with at least one soft tissue lesion measurable at 1 centimeter (cm) or greater in short axis measurement on cross sectional imaging such as Computerized tomography (CT), Magnetic resonance imaging (MRI), or Positron Emission Tomography (PET)/CT.
- Clinically able to undergo PET/CT imaging.
- Age \geq 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of \leq 2 or Karnofsky \geq 50%.

... and 8 more (see full listing online)

Exclusion (7)

- Individuals with a contraindication to PET-CT imaging (e.g., severe claustrophobia).
- Individuals who are pregnant or breastfeeding/chestfeeding. Pregnant and breastfeeding/chestfeeding individuals are excluded because there is an unknown but potential risk for adverse effects in the unborn/nursing child secondary to treatment of the study participant with [89Zr]DFO-starPEG. Females of childbearing potential must have a negative pregnancy test before administration of [89Zr]DFO-starPEG, as outlined in inclusion criterion #7. Breastfeeding/chestfeeding should be discontinued before administration of [89Zr]DFO-starPEG.
- Individuals who do not agree to follow the below contraception requirements:
 - Females of reproductive potential (defined below) must agree to use two forms of contraception, consisting of a barrier method (such as condoms) in combination with a secondary complementary method (such as hormonal, intrauterine device (IUD), etc.), or strict abstinence, for the duration of study participation and for 1 month after administration of [89Zr]DFO-starPEG.
 - A female is considered to NOT be of reproductive potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a postmenopausal state (\geq 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries).

... and 2 more (see full listing online)

Locations (1 total)

University of California, San Francisco, San Francisco, California, United States

<https://clinicaltrials.gov/study/NCT06894745>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.